Search results
Showing 631 to 645 of 2208 results for guidelines
COVID-19 rapid guideline: arranging planned care in hospitals and diagnostic services (NG179)
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care (HTG682)
Evidence-based recommendations on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COPD see our guideline on diagnosing and managing COPD in over 16s and for people with COVID-19 see our guideline on managing COVID-19.
Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults.
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community (NG163)
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
Read biographies for all members of NICE's indicator advisory committee.
Mirabegron for treating symptoms of overactive bladder (TA290)
Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
Awaiting development Reference number: GID-TA10439 Expected publication date: TBC
Awaiting development Reference number: GID-TA10438 Expected publication date: TBC
Rivaroxaban for preventing venous thromboembolism after hip or knee replacement surgery (TA170)
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing venous thromboembolism after hip or knee replacement in adults.
View recommendations for TA170Show all sections
Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.